Novo Nordisk doses first subject in Phase I trial of NLRP3 inhibitor [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Ventus Therapeutics licenced NNC6022-0001 to Novo Nordisk in September 2022. The study aims to thoroughly evaluate the pharmacokinetics, pharmacodynamics, and safety profile of NNC6022-0001. It will involve a broad range of doses administered to healthy volunteers. Under an exclusive development and licensing agreement announced in September 2022, Novo Nordisk obtained global rights for the development and commercialisation of Ventus' leading NLRP3 inhibitor programme for various indications. The programme targets a variety of diseases, including metabolic dysfunction-associated non-alcoholic steatohepatitis (MASH), chronic kidney disease, and other cardiometabolic conditions. In exchange for the licensing rights, Ventus obtained $70m in upfront payment, along with ongoing research and development funding. Additionally, Ventus is entitled to receive up to $633m in potential clinical, regulatory, and commercial milestones, as well as tiered royalties on future sales. Nov
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- 4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]Yahoo! Finance
- Succession drama grips Gucci as sales fail to make the cut [Yahoo! Finance]Yahoo! Finance
- Temedica Expands Its Advisory Board With Former Gematik CEO Markus Leyck Dieken [Yahoo! Finance]Yahoo! Finance
- Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 5/17/24 - Form 6-K
- 5/17/24 - Form SD
- 5/15/24 - Form 6-K
- NVO's page on the SEC website